Efficacy of sonidegib for basal cell carcinoma in a patient affected by multiple infectious diseases

Dermatol Ther. 2021 Jul;34(4):e14969. doi: 10.1111/dth.14969. Epub 2021 May 9.

Authors

Luca Fania¹, Elena Dellambra², Gaia Moretta¹, Elisabetta Grilli³, Christiana Zorika Di Rocco⁴, Francesca Maria Morelli⁴, Albina Rita Zappalà⁴, Damiano Abeni⁵, Roberto Morese⁴

Affiliations

¹ Department of Dermatology, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy.
² Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy.
³ UOC Viral Immunodeficiencies, INMI L. Spallanzani, Rome, Italy.
⁴ Department of Oncology, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy.
⁵ Clinical Epidemiology, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy.

PMID: 33928734
DOI: 10.1111/dth.14969

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Biphenyl Compounds
Carcinoma, Basal Cell* / drug therapy
Communicable Diseases*
Humans
Pyridines / therapeutic use
Skin Neoplasms* / drug therapy

Substances

Antineoplastic Agents
Biphenyl Compounds
Pyridines
sonidegib